Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Alaunos Therapeutics, Inc. Director's Dealing 2012

Jan 4, 2012

35407_dirs_2012-01-04_649b3c13-e03c-4f7f-9f45-499ef8d7cebf.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ZIOPHARM ONCOLOGY INC (ZIOP)
CIK: 0001107421
Period of Report: 2011-12-30

Reporting Person: BELBEL CAESAR J (EVP, CLO, and Secretary)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2011-12-30 Common Stock A 21578 $0.00 Acquired 21578 Direct

Footnotes

F1: 7,193 shares vest on each of 12/30/2012 and 12/30/2013; and 7,192 shares vest on 12/30/2014.